Characterization of Novel Antibiotic Resistance Genes in Staphylococcal aureus

Abstract

Despite many efforts to control resistance phenomenon, antibiotic resistance in Staphylococcus aureus. The evolution of increasingly antimicrobial resistant in Staphylococcus aureus stems from a multitude factors that involve the widespread and sometimes unsuitable utilize of antimicrobials. The use of Methicillin and Vancomycin were very effective against Staph aureus, but using genetic versatility they have adapted resistance to these antibiotics, and methicillin resistance and vancomycin resistance strains developed. Resistance can be to a quantity of extent contained by a smaller amount and better use of antibiotics, but ultimately novel molecular mechanisms required for treatment and control of antibiotic resistance. The present study will focus on the identification of novel genes and their mechanism in S. aureus strains and focus on some new targets for therapeutic agents against these antibiotic resistance strains.

Keywords: Staphylococcal aureus; Antibiotic; Methicillin; Vancomycin; Therapeutic

Introduction

S. aureus is possibly the pathogen of most concern because of its intrinsic virulence, its ability to cause a diverse array of life threatening infections, and its capacity to adapt to different environmental conditions [1]. The mortality of S. aureus bacteraemia remains just about 20-40% despite the accessibility of effective antimicrobials. S. aureus is now the leading source of nosocomial infections and, as more patients are treated outside the hospital setting, is a rising concern in the community [2,3]. Recent reports of S. aureus isolates with intermediate, and whole resistance to vancomycin portend a chemotherapeutic era in which effectual bactericidal antibiotics against this organism may no longer be available [4]. The irony of this trend toward progressively more resistant bacteria is that it coincides with a period of increased understanding of the molecular mechanisms of antimicrobial resistance. Unfortunately, while this insight has resulted in the identification of novel drug targets, it has not yet resulted in effective new chemotherapeutic agents.

The introduction of penicillin in the near the beginning the 1940s considerably improved the prognosis of patients with Staphylococcal infection. Though, as near the beginning as 1942, penicillin-resistant staphylococci were recognized, first in hospitals and subsequently in the community [5]. The late 1960s, further more 80% of both Community, as well as hospital, acquired staphylococcal isolates were resistant to penicillin. More than 90% of staphylococcal isolates at present generate penicillinase, regardless of the clinical setting [2].

Methicillin was the first of the semisynthetic penicillinase resistant penicillins introduced in 1961, its introduction quickly followed by reports of methicillin-resistant isolates [6]. Also, the existence of virulence genes such as the enterotoxins or the Panton-Valentine leukocidin, the meca gene is the main agent for methicillin resistance and is part of a mobile genetic element found in all MRSA strains [7], demonstrated that meca A is part of a genomic island designated staphylococcal cassette chromosome mec (SCCmec).

The recent upsurge of community acquired MRSA infections reported in patients from dissimilar countries associated with the finding of a unique SCCmec, type IV [8]. This element, smaller than the other elements, appears more genetically mobile and does not carry extra antimicrobial resistance genes. It also appears to occur in an additional varied range of MSSA genetic backgrounds, signifying that it has been heterologously transferred additional readily from further staphylococcal species [9]. Staphylococcal resistance to vancomycin in a clinical isolate first reported in a strain of Staphylococcus haemolyticus [10]. The initial report of vancomycin intermediate-resistant S. aureus (VISA) In 1997 came from Japan, and supplementary cases afterward reported from other countries. The VISA isolates were every one MRSA and were not clonal. Numerous of the patients had received vancomycin therapy and had MRSA infections [11]. Fluoroquinolones was at first introduced for the
conduct of Gram-negative bacterial infections in the 1980s [12]. Due to their Gram-positive bacterial spectrum, they have as well used to diagnose bacterial infections caused by *pneumococci* and *staphylococci* [2].

**Mechanisms of Antibiotics Resistance in *S. aureus***

Staphylococcal is mediated by blaZ, resistance to penicillin, the gene encodes β-lactamase. The gene is part of a transposable element located on a large plasmid, often with additional antimicrobial resistance genes. This predominantly extracellular enzyme, synthesized while staphylococcal are showing to β-lactam antibiotics, hydrolyzes the β-lactam ring, rendering the β-lactam inactive. The blaZ is under the control of two adjacent regulatory genes, the antirepressor blaR1 and the repressor blaI [11]. Current studies have verified that the signaling pathway responsible for β-lactamase synthesis requires sequential cleavage of the regulatory proteins BlaR1 and BlaI.

Quinolone resistance among *S. aureus* emerged rapidly, additional prominently among the methicillin-resistant strains. As a result, the capability to use fluoroquinolones as anti-staphylococcal agents dramatically reduced [15]. The reasons for the disparity in rates of quinolone resistance between MSSA and MRSA strains are unsure. One causative factor is likely antibiotic selective pressure, particularly in the hospital setting, resulting in the choice and spread of the extra antibiotic-resistant MRSA strains resistance to quinolones outcome from the stepwise acquisition of chromosomal mutations. The confluence of high bacterial density, the possible pre existence of resistant sub populations, and the from time to time limited quinolone concentrations achieved at sites of staphylococcal infections create an environment that fosters selection of resistant mutants [11].

**Novel Targets and Mechanisms**

The supply of innovative agents with novel mechanisms of action is limited, however, emphasizes the need for the development of new drug targets [16]. Unfortunately, an increasing number of pharmaceutical companies have either eliminated or dramatically reduced their anti-infective units. This outcome partly from economic considerations but also from frustration that target-based biochemical screening has unsuccessful to build up some clinically useful products.

The failure has been recognized, in part to the recognition that target-based strategies do not get into account the intrinsic mechanisms of bacterial resistance (biofilms, multidrug efflux pumps) to contribute in vivo bacterial resistance [17]. Despite these developments, some attractive models for recognition of novel drug targets have emerged.

One approach has been to integrate genomic instructions and discover novel resistance genes on possible drug targets with a high-throughput screening followed by chemical modification and efficacy in an animal model. There has been a transformed attention in the characterization of essential components of serious biosynthetic pathways (fatty acid biosynthesis or peptidoglycan assembly) as potential targets [18]. Many dissimilar techniques, as well as *in vivo* expression technology, signature-tagged mutagenesis, and detection of expressed *S. aureus* antigens, have been used to recognize potential targets that expressed during infection. Examination of the crystal structure of drug targets (modifications of β-lactams that hit the active site of PBP2a) also the synthesis of carbohydrate-modified compounds (glycopeptide analogs among altered carbohydrates) are gradually more used to develop alternative agents [19]. Phenol-soluble modules and S. adenosyl homocysteine nucleosidase can serve as anti-staphylococcal targets [20]. Modification of *S. aureus* genes linked with virulence reduces infectivity [21,22]. Whether these genes can effectively use as potential targets is uncertain.

**Conclusion**

The study determines the possible antibiotic targets that can improve the efficacy of pre-existing antibiotic and would propose an idea for the new antibacterial. Some new mechanisms of resistance will discover that can further elaborate *S. aureus*.
pathogenesis and will help in other pathogens virulence. We propose new molecular pathways that can reduce the emergence of antibiotic resistance in \textit{S. aureus}.

**Acknowledgement**

None.

**Conflict of Interest**

None.

**References**

5. Skinner D, Keefer CS (1941) Significance of bacteremia caused by \textit{Staphylococcus aureus}: a study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Archives of Internal Medicine 68(5): 851-875.